Japan Tissue Engineering Co., Ltd. (JP:7774) has released an update.
Japan Tissue Engineering Co., Ltd. has announced the National Health Insurance listing of its innovative treatment for vitiligo, ‘JACEMIN’, starting October 1, 2024. ‘JACEMIN’ is a regenerative medical product that transplants autologous cultured epidermis, maintaining melanocytes to restore pigmentation in patients. This low-invasive treatment is expected to significantly improve the quality of life for vitiligo patients in Japan.
For further insights into JP:7774 stock, check out TipRanks’ Stock Analysis page.